Infectious disease treatment: Key market research findings
- Increasing levels of pollutants and chemicals is the primary driver for the market
- Increase in number of collaborations and M&As
- Key vendors—F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, and Pfizer
Technavio’s market research analysts estimate the infectious disease treatment market in China to grow at a CAGR of over 5% between 2016 and 2020. The increase in exposure to chemicals and pollutants is the primary driver for the market. The level of pollutants in the atmosphere is on the rise due to increased industrialization and automobile use. Pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to cause diseases like chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other respiratory issues. At present, the antibacterial drugs segment holds around a 64% stake in the market to dominate the infectious disease treatment market in China. The increasing prevalence of infectious diseases and high unmet medical needs are factors that will boost growth in this segment of the infectious disease treatment market in China by 2020.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“An increase in the number of collaborations and mergers and acquisitions (M&As) is the latest trend in the market. Collaborations are aimed at lowering the prevalence of infectious diseases while M&As are targeted at improving market penetration of the acquirer or enhance the product portfolio of the parent company. For instance, in February 2012, BMS acquired Inhibitex to enhance its portfolio of hepatitis C investigational drugs,” Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
Physicians are currently attempting to bring down the prevalence of infectious diseases by prescribing drugs that are a combination of an anti-infective and a corticosteroid. Anti-infectives help reduce infection while corticosteroids lessen the inflammation. Anti-infectives take a longer time for disease remission when used alone. For instance, Zerbaxa and Avycaz prove the acceptance of combination therapies for the treatment of infections. The increasing adoption of combination therapies is projected to reflect positively on the market in the coming years.
The key vendors in the infectious disease treatment market in China include F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, and Pfizer. The infectious disease treatment market in China is highly competitive owing to the presence of several well-established small and large providers. The market has tremendous growth opportunities which are resulting in a lot of new players exploring the market. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.
A more detailed analysis is available in the Technavio report, Infectious Disease Treatment Market in China 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
